CoChat

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Open access
Syversen, Silje Watterdal, Jørgensen, Kristin Kaasen, Goll, Guro Løvik, Brun, Marthe Kirkesæther, Sandanger, Øystein, Bjørlykke, Kristin Hammersbøen, Sexton, Joseph, Olsen, Inge Christoffer, Gehin, Johanna Elin, Warren, David John, Klaasen, Rolf Anton, Noraberg, Geir, Bruun, Trude Jannecke, Dotterud, Christian Kvikne, Ljoså, Maud Kristine Aga, Haugen, Anne Julsrud, Njålla, Rune Johan, Zettel, Camilla, Ystrøm, Carl Magnus, Bragnes, Yngvill Hovde, Skorpe, Svanaug, Thune, Turid, Seeberg, Kathrine Aglen, Michelsen, Brigitte, Blomgren, Ingrid Marianne, Strand, Eldri Kveine, Mielnik, Pawel, Torp, Roald, Mørk, Cato, Kvien, Tore K., Jahnsen, Jørgen, Bolstad, Nils, Haavardsholm, Espen A. · 2021 · JAMA
Cited by 167

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Importance: Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum drug levels, has been proposed as an alternative to standard therapy to optimize efficacy and safety of infliximab and other biologic drugs. However, it remains unclear whether proactive TDM improves clinical outcomes during maintenance therapy. Objective: To assess whether proactive TDM during maintenance therapy with infliximab improves treatment efficacy by preventing disease worsening compared with standard infliximab therapy without TDM. Design, Setting, and Participants: Randomized, parallel-group, open-label clinical trial including 458 adults with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis undergoing maintenance therapy with infliximab in 20 Norwegian hospitals. Patients were recruited from June 7, 2017, to December 12, 2019. Final follow-up took place on December 14, 2020. Interventions: Patients were randomized 1:1 to proactive TDM with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (TDM group; n = 228) or to standard infliximab therapy without drug and antibody level monitoring (standard therapy group; n = 230). Main Outcome and Measures: The primary outcome was sustained disease control without disease worsening, defined by disease-specific composite scores or consensus about disease worsening between patient and physician leading to a major change in treatment (switching to another biologic drug, adding an immunosuppressive drug including glucocorticoids, or increasing the infliximab dose), during the 52-week study period. Results: Among 458 randomized patients (mean age, 44.8 [SD, 14.3] years; 216 women [49.8%]), 454 received their randomly allocated intervention and were included in the full analysis set. The primary outcome of sustained disease control without disease worsening was observed in 167 patients (73.6%) in the TDM group and 127 patients (55.9%) in the standard therapy group. The estimated adjusted difference was 17.6% (95% CI, 9.0%-26.2%; P < .001) favoring TDM. Adverse events were reported in 137 patients (60%) and 142 patients (63%) in the TDM and standard therapy groups, respectively. Conclusions and Relevance: Among patients with immune-mediated inflammatory diseases undergoing maintenance therapy with infliximab, proactive TDM was more effective than treatment without TDM in sustaining disease control without disease worsening. Further research is needed to compare proactive TDM with reactive TDM, to assess the effects on long-term disease complications, and to evaluate the cost-effectiveness of this approach. Trial Registration: ClinicalTrials.gov Identifier: NCT03074656.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2021.21316

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 167

Metadata

Authors
Syversen, S. W., Jørgensen, K. K., Goll, G. L., Brun, M. K., Sandanger, Ø., Bjørlykke, K. H., Sexton, J., Olsen, I. C., Gehin, J. E., Warren, D. J., Klaasen, R. A., Noraberg, G., Bruun, T. J., Dotterud, C. K., Ljoså, M. K. A., Haugen, A. J., Njålla, R. J., Zettel, C., Ystrøm, C. M., Bragnes, Y. H., Skorpe, S., Thune, T., Seeberg, K. A., Michelsen, B., Blomgren, I. M., Strand, E. K., Mielnik, P., Torp, R., Mørk, C., Kvien, T. K., Jahnsen, J., Bolstad, N., & Haavardsholm, E. A.
Venue
JAMA
Published
2021-12-21
Volume
326
Issue
23
Pages
2375
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4200136929
Cited by
167
References
5
FWCI
17.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2021.21316
The paper
Syversen, S. W., Jørgensen, K. K., Goll, G. L., Brun, M. K., Sandanger, Ø., Bjørlykke, K. H., Sexton, J., Olsen, I. C., Gehin, J. E., Warren, D. J., Klaasen, R. A., Noraberg, G., Bruun, T. J., Dotterud, C. K., Ljoså, M. K. A., Haugen, A. J., Njålla, R. J., Zettel, C., Ystrøm, C. M., . . . Haavardsholm, E. A. (2021). Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2021.21316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.